← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Janessen Vaccines And Prevention, Bv
Leiden
$125,006,856
Total funding
3
Grants
Funding over time
peak $48.4M · FY2008–22$50M$37.5M$25M$12.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$125,006,856 · 3
By mechanism
N01$125,006,856 · 3
Investigators at Janessen Vaccines And Prevention, Bv
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of Human Anti-Influenza Monoclonal Antibodies for Treatment of Flu$27,536,741
N01 · FY2010 · AI
Advanced Development of Multivalent Filovirus Vaccines$20,885,825
N01 · FY2010 · AI
Advanced Development of an Ebola Vaccine$14,483,618
N01 · FY2016 · AI
Development of Human Anti-Influenza Monoclonal Antibodies for Treatment of Flu$13,677,248
N01 · FY2013 · AI
Advanced Development of Multivalent Filovirus Vaccines$13,496,364
N01 · FY2008 · AI
Development of Human Anti-Influenza Monoclonal Antibodies for Treatment of Flu$13,246,602
N01 · FY2009 · AI
Development of Human Anti-Influenza Monoclonal Antibodies for Treatment of Flu$8,118,206
N01 · FY2012 · AI
Advanced Development of an Ebola Vaccine$8,069,468
N01 · FY2014 · AI
Advanced Development of Multivalent Filovirus Vaccines$4,000,000
N01 · FY2013 · AI
Advanced Development of a Filovirus Vaccine$881,157
N01 · FY2018 · AI
Advanced Development of a Filovirus Vaccine$611,627
N01 · FY2022 · AI